InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.010 -0.001 (-9.09%)+
Announcement
Release
19 Feb 2026 10:08AM
Price at Release
$0.011
Full Release
download
Summary
Anatara Lifesciences Ltd is advancing its Anti-Obesity Project with compound AOC, which has shown promising results in reducing weight gain and visceral fat in pre-clinical studies. The company plans further human studies to assess its efficacy and potential for commercialization. Alongside, Anatara evaluates strategic opportunities and maintains a focus on unmet medical needs. Their GaRP Project in gastrointestinal health continues to be a priority, backed by solid patent protection.
Key Points
  • Anatara Lifesciences Ltd is developing innovative, evidence-based health products addressing unmet medical needs.
  • The Anti-Obesity Project focuses on an oral complementary medication to aid weight reduction and control.
  • Compound AOC has shown significant reduction in weight gain and visceral fat in pre-clinical studies.
  • Mechanism of Action (MOA) studies were inconclusive, necessitating further studies.
  • Anatara plans a limited human pharmacokinetic study to evaluate AOC's efficacy.
  • Corporate activities include evaluating strategic directions and potential transactions.
  • The GaRP Project focuses on gastrointestinal health with patent protection in place.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.